Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Pfizer accuses former employees of trade secret theft

By Brian Buntz | February 3, 2022

PfizerPfizer (NYSE:PFE) is suing Regor Therapeutics, a China-headquartered company that announced a $1.5 billion diabetes alliance with Eli Lilly (NYSE:LLY) in late 2021.

Filed in the U.S. District Court for the District of Delaware, Pfizer’s lawsuit also accuses former employees Xiayang Qiu, Min Zhong and 10 unnamed individuals of using its trade secrets as the basis for the company Regor Therapeutics (Shanghai), which was founded in 2018. The two also established a secondary company known as QILU Regor Therapeutics, also named in the suit.

Specifically, Pfizer accuses Regor of poaching from its diabetes and obesity pipeline, including glucagon-like peptide 1 (GLP-1) receptor agonist candidates. In late 2016, Pfizer filed a patent application describing more than 250 small-molecule compounds that were the fruits of a 14-year-long R&D initiative, including GLP-1 receptor agonists.

Pfizer is seeking damages and injunctive relief in the case, including reassigning applicable Regor patents to Pfizer.

The suit alleges that the defendants misappropriated trade secrets in violation of the Defend Trade Secrets Act and violated the Connecticut Unfair Trade Practices Act. In addition, it accuses the defendants of breach of fiduciary duty, breach of duty of loyalty under Connecticut law and breach of contract under New York law.

Pfizer said it concluded through forensic research that the Regor co-founders used numerous devices and accounts to steal trade secrets.

Regor Therapeutics did not immediately respond to a request for comment.

The co-founder and current CEO of Regor Therapeutics, Xiayang Qiu, worked as an executive at Pfizer from 2001 to 2018. According to his LinkedIn profile, Qiu was involved in developing 29 candidates across a range of therapeutic areas.

Min Zhong, Regor’s chief operating officer, worked at Pfizer from 2007 to 2018.

In Regor’s collaboration with Lilly, the company received an upfront payment of up to $50 million an additional $1.5 billion in potential milestone payments.

In a press release, Qiu boasted of establishing a “world-class research organization” in a little over three years.

The case is titled Titled “Pfizer v. Regor Therapeutics Inc., Qilu Regor Therapeutics Inc., Xiayang Qiu, Min Zhong, and Does 1-10.” The case number is 3:22-cv-190.


Filed Under: Cardiovascular, Drug Discovery, Metabolic disease/endicrinology
Tagged With: Diabetes, Eli Lilly, intellectual property, IP, obesity, Pfizer, Regor Therapeutics
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Shifting GLP-1 research and development: Lessons learned from the first-generation 
Pens to pills: what oral GLP-1s change at the bench
ADA conference roundup: GLP-1 trial results and researchers removed by police
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE